EGFR and non-small cell lung carcinoma: QUADRUPLE THREAT is an exploratory open-label phase 2 study evaluating the use of RRx-001 priming followed by re-challenge with platinum-based chemotherapy in patients with previously treated SCLC, EGFR mutated non-small-cell lung cancer (NSCLC), high-grade neuroendocrine tumours and ovarian tumours.